The mechanism of G protein-coupled receptor (GPCR) signal integration is controversial. While GPCR assembly into hetero-oligomers facilitates signal integration of different receptor types, cross-talk between Gai-and Gaqcoupled receptors is often thought to be oligomerization independent. In this study, we examined the mechanism of signal integration between the Gai-coupled type I cannabinoid receptor (CB 1 R) and the Gaq-coupled AT1R. We find that these two receptors functionally interact, resulting in the potentiation of AT1R signalling and coupling of AT1R to multiple G proteins. Importantly, using several methods, that is, co-immunoprecipitation and resonance energy transfer assays, as well as receptor-and heteromerselective antibodies, we show that AT1R and CB 1 R form receptor heteromers. We examined the physiological relevance of this interaction in hepatic stellate cells from ethanol-administered rats in which CB 1 R is upregulated. We found a significant upregulation of AT1R-CB 1 R heteromers and enhancement of angiotensin II-mediated signalling, as compared with cells from control animals. Moreover, blocking CB 1 R activity prevented angiotensin II-mediated mitogenic signalling and profibrogenic gene expression. These results provide a molecular basis for the pivotal role of heteromer-dependent signal integration in pathology.
Introduction
The angiotensin II (Ang II) type 1 receptor (AT1R) is a G protein-coupled receptor (GPCR) that transduces the main physiological actions of the renin-angiotensin system in target cells. The major signalling events following agonist binding to this receptor are activation of phospholipase C via a Gaq protein, mobilization of calcium from intracellular stores, and activation of other signalling pathways such as the MAP kinase pathway that participates in the hypertrophic actions of Ang II . AT1R is primarily involved in the control of blood pressure as demonstrated in numerous animal models (Ito et al, 1995; Sugaya et al, 1995; Le et al, 2003) . Using functional complementation experiments, AT1R was among the first class A GPCR to be proposed to function as a dimer , and formation of AT1R heteromers was later found to be involved in pathology (Barki-Harrington, 2004) . For instance, the contribution of AT1R to specific forms of hypertension has been shown to be regulated by interactions with B2 bradykinin receptor (AbdAlla et al, 2001) , and recently, physical interactions with the apelin receptor was proposed to regulate the atherosclerotic effect of Ang II (Chun et al, 2008) , suggesting that heteromerization of AT1R with other GPCRs contributes to the pathophysiological effects of Ang II. In addition to its role in blood pressure regulation, AT1R hypertrophic properties contribute to the development of fibrosis in a number of organs. However, the molecular or cellular events that cause AT1R to become profibrogenic remain elusive.
Type I cannabinoid receptor (CB 1 R) is widely expressed in the brain and essentially absent in peripheral tissues under normal conditions. The development of an antibody specifically recognizing the dimeric CB 1 R demonstrated that this receptor exists as homodimers (Wager-Miller et al, 2002) . In addition, CB 1 R has been shown to form heteromers with a number of other GPCRs, leading to an alteration in receptor coupling as in the case of CB 1 R-D2 dopamine receptor (Kearn et al, 2005) , trafficking, as in the case of CB 1 R-orexin-1 receptor (Ellis et al, 2006) , and signalling, as in the case of CB 1 R-A2aR (Carriba et al, 2007) .
CB 1 R is upregulated in some peripheral tissues during chronic diseases, such as liver fibrosis. CB 1 R exhibits marginal expression in the normal liver but a robust expression in fibrotic liver, predominantly in activated hepatic stellate cells (HSCs) (Teixeira-Clerc et al, 2006) ; these cells are primarily responsible for the fibrogenic response in the liver (Friedman, 2008) . HSCs also express AT1R (Pereira et al, 2009) , and both AT1R and CB 1 R antagonists exhibit anti-fibrotic properties (Teixeira-Clerc et al, 2006; Schuppan and Afdhal, 2008) .
Here, we propose that enhanced CB 1 R expression in activated HSCs could affect AT1R properties and contribute to the profibrogenic effect of Ang II. Given the implication of heteromerization in the pathophysiological function of both CB 1 R and AT1R, it was of interest to determine whether such a AT1R-CB 1 R heteromer exists and could be selectively targeted pharmacologically, or if cross-talk between AT1R and CB 1 R could result from heteromerization-independent functional interactions, as previously reported for other Gaq-and Gai-coupled receptor pairs (Rives et al, 2009) .
We first probed the interaction between AT1R and CB 1 R in recombinant systems using biophysical and biochemical methods and found that the two receptors associate. This association leads to changes in coupling and enhanced signalling by AT1R that could be blocked by heteromerselective antibodies. We also found that the AT1R-mediated signalling is controlled by CB 1 R. For example, basal endocannabinoid tone enhances Ang II-mediated signalling and CB 1 R antagonists block AT1R-mediated signalling. We then examined the consequences of AT1R-CB 1 R interaction on Ang II-mediated profibrogenic responses in activated HSCs. We show that AT1R interacts with CB 1 R to form heteromers in these cells, and this facilitates the profibrogenic effect of Ang II. These results provide evidence for the contribution of heteromer-directed signal specificity in pathology.
Results
Ang II-mediated ERK phosphorylation is altered in the presence of CB 1 R We first examined the effect of CB 1 R coexpression on AT1R signalling. We took advantage of Neuro2A cells, a neuroblastoma cell line that contains endogenous CB 1 R to examine Representative western blot analysis of Neuro2A-AT1R cells transfected with control or CB 1 R-targeting siRNA and probed for the levels of CB 1 R (B70% decrease with CB 1 R siRNA), AT1R (no change) and calnexin as a loading control. Mean±s.e.m. densitometry from three independent transfections are indicated below the western blot. ***Po0.001. (C) Neuro2A-AT1R cells starved for 4 h, were stimulated with increasing concentrations of Ang II for 3 min, in the presence of the CB 1 R antagonist (SR141716; 1 mM) or in the presence of a non-signalling dose of the CB 1 R agonist (Hu210; 0.1 nM). Data represent mean ± s.e.m. (n ¼ 3-5). **Po0.01; ***Po0.001. (D) Phospho-ERK levels after Ang II stimulation were examined in Neuro2A-AT1R cells, after treatment with the diacylglycerol lipase inhibitor THL (1 mM; 2 h pretreatment) alone or together with Hu210 (0.1 nM); or, (E) with increasing concentrations of 2-AG. Data are expressed as the mean±s.e.m. (n ¼ 3-4). **Po0.01; ***Po0.001; NS, non-significant. Cell lysates were subjected to western blotting analysis using antibodies to pERK and ERK (1:1000). Imaging and quantification was carried out using the Odyssey Imaging system (Li-Core Biosciences).
functional interactions of CB 1 R with AT1R. For this, we generated stable cell lines expressing an N-terminally Flag-tagged AT1R (Neuro2A-AT1R), and explored the modulation of AT1R function by CB 1 R. Stimulation with Ang II led to a rapid, robust, and dose-dependent increase in pERK levels ( Figure 1A ; Supplementary Figure S1A ). This was blocked by pretreatment with the specific AT1R antagonist Losartan, and was dependent on AT1R since wild-type (non-transfected) Neuro2A cells did not respond to Ang II (Supplementary Figure S1A) . We examined if the presence of CB 1 R contributed to the response of AT1R to Ang II stimulation, by directly altering CB 1 R expression. RNAi-mediated CB 1 R downregulation (see Figure 1B) led to a dramatic decrease (by B50%) in Ang II-mediated signalling ( Figure 1A ; Supplementary Figure S1A ). Dose response experiments indicated that CB 1 R affects AT1R signalling by increasing the efficacy of Ang II ( Figure 1A ).
CB 1 R activation determines Ang II efficacy
Next, we examined the extent of involvement of CB 1 R activity in Ang II-mediated signalling using CB 1 R-specific ligands. The CB 1 R selective antagonist SR141716 (rimonabant) blocked by 470% Ang II response ( Figure 1C ) while the CB 1 R agonist Hu210 potentiated this response ( Figure 1C ). Since CB 1 R antagonist blocked AT1R signalling, we hypothesized that in the absence of exogenous CB 1 R ligand, CB 1 Rmediated increase in Ang II efficacy could be the result of activation of CB 1 R by endocannabinoids. We tested this possibility by inhibiting the production of the endocannabinoid 2-arachidonoyl glycerol (2-AG). Blocking the enzyme, diacylglycerol lipase (DAGL), responsible for 2-AG production, with the DAGL inhibitor THL, led to a complete blockade of Ang II response ( Figure 1D ). We also examined if the addition of exogenous CB 1 R agonists (Hu210 or 2-AG) could reverse the effect of THL treatment. In the presence of THL, addition of Hu210 or 2-AG was able to restore Ang II-mediated signalling ( Figure 1E ). The effect of cannabinoid ligands on Ang II-mediated ERK phosphorylation was not observed upon RNAi-mediated downregulation of CB 1 R (Supplementary Figure S1B ). The potentiating effect of CB 1 R activity on Ang II-mediated signalling was not restricted to ERK signalling, since other signalling events such as Ang IIinduced p38 and JNK phosphorylation were also attenuated by downregulating CB 1 R (Supplementary Figure S2A) . Blockade of Ang II-mediated ERK phosphorylation by SR141716 or by THL could also be seen in HEK293 cells coexpressing AT1R and CB 1 R, but not in cells expressing AT1R alone (Supplementary Figure S2B) . Together, these data indicate that AT1R signalling is controlled by CB 1 R activity. In the absence of exogenous cannabinoid ligands, endocannabinoid-mediated basal CB 1 R activation is sufficient to allow and potentiate AT1R signalling.
AT1R physically interacts with CB 1 R Using a variety of approaches, we examined if the functional interaction between CB 1 R and AT1R was the consequence of physical interaction (heteromerization) between these two receptors. First, we carried out co-immunoprecipitation experiments and detected interaction between CB 1 R and AT1R only in cells coexpressing the two receptors ( Figure 2A ). This interaction was also supported by colocalization of Flag-AT1R with CB 1 R in Neuro2A-AT1R cells ( Figure 2B ). Since individually expressed AT1R is at the plasma membrane and CB 1 R is in intracellular compartments (Pignatari et al, 2006; Rozenfeld and Devi, 2008) , we examined changes in CB 1 R and AT1R localization upon coexpression of the receptors in HEK293 cells (Supplementary Figure  S2C) . We find that when coexpressed with AT1R, CB 1 R was found primarily at the plasma membrane colocalized with AT1R (Supplementary Figure S2D) , supporting an association between the two receptors since such a change in receptor localization has been previously reported to be due to receptor heteromerization (Ellis et al, 2006) . We then used bioluminescence resonance energy transfer (BRET) technology that allows the detection of energy trans- Figure 2 Interaction between AT1R and CB 1 R. (A) Association of AT1R and CB 1 R in Neuro2A-AT1R. Lysates from Neuro2A and Neuro2A-AT1R were subjected to immunoprecipitation using a protein A agarose-coupled anti-CB 1 R antibody (1 mg), and to western blotting analysis with an anti-AT1R antibody (1:200). AT1R is detected in the CB 1 R immunoprecipitate from Neuro2A-AT1R. (B) Immunofluorescence and confocal microscopy analysis of Neuro2A cells expressing endogenous CB 1 R and of Neuro2A cells stably expressing Flag-AT1R. Cells grown on coverslips were fixed with 4% PFA, permeabilized in 0.1% Triton X-100, and stained with primary rabbit polyclonal anti-CB 1 R (1:500) and mouse monoclonal M2 anti-Flag (1:1000) antibodies. After fluorescent secondary antibody staining, the coverslips were mounted with mowiol. Slides were examined with a Leica SP5 confocal microscope. (C) Detection of AT1R-CB 1 R heteromers by BRET in living HEK293 cells. BRET experiments were carried out using C-terminally Renilla luciferase-tagged CB 1 R, and eGFP-tagged AT1R (B400-500 fmol receptor/mg protein). BRET ratio was measured in cells expressing the indicated constructs. To assess the specificity of interaction, BRET ratios were measured in cells coexpressing increasing concentrations of untagged AT1R, in cells coexpressing untagged endothelin converting enzyme-2, or in cells coexpressing MOR-Luc with AT1R-eGFP. In addition, BRET saturation curve was generated (insert). HEK-293 cells were co-transfected with a constant DNA concentration of CB 1 R-Rluc and increasing DNA concentrations of AT1R-eGFP. Curves were fitted using a non-linear regression equation assuming a single binding site (GraphPad Prism). Results are mean values±s.e.m. (n ¼ 3 experiments). ***Po0.001; NS, nonsignificant, versus CB 1 R-Luc/AT1R-eGFP. (D) Detection of AT1R-CB 1 R heteromers with heteromer-selective monoclonal antibodies. Receptor abundance was determined in Neuro2A, Neuro2A-AT1R, and Neuro2A-AT1R cells where CB 1 R was downregulated by RNAi (Neuro2A-AT1R siCB 1 R) with a monoclonal antibody to AT1R-CB 1 R, or polyclonal antibodies to AT1R or CB 1 R by ELISA. Results are mean values ± s.e.m. (n ¼ 3 experiments). ***Po0.001; NS, non-significant, versus Neuro2A-AT1R. (E) Inhibition of AT1R-CB 1 R signalling by the AT1R-CB 1 R heteromer antibody. Neuro2A-AT1R and Neuro2A-AT1R cells where CB 1 R was downregulated by RNAi (Neuro2A-AT1R/siCB 1 R) were incubated with increasing concentrations of the monoclonal anti-AT1R-CB 1 R antibody (hydridoma supernatant, þ , 1:20 v/v; þ þ , 1:10 v/ v; þ þ þ , 1:5 v/v; þ þ þ þ , 2:5 v/v) for 30 min, and then were stimulated with 10 nM Ang II for 3 min. Cell lysates and media were subjected to western blotting analysis using antibodies to pERK and ERK (1:1000) (lysate) and anti-mouse IgG (media). Imaging and quantification were carried out using the Odyssey Imaging system (Li-Core Biosciences). fer between one receptor bearing the BRET donor (Renilla luciferase) and the second receptor bearing the acceptor (green fluorescent protein) when the two receptors are in close proximity (o50 Å ) (Angers et al, 2000) . Under these conditions, we observed a highly significant BRET signal in cells coexpressing tagged AT1R and CB 1 R ( Figure 2C 1.25 0 1 e -1 1 1 e -1 0 1 e -9 1 e -8 1 e -7 0 1 e -1 1 1 e -1 0 1 e -9 1 e -8 1 e -7 0 1 e -1 1 1 e -1 0 1 e -9 1 e -8 1 e -7
significant BRET signal was observed in cells coexpressing mu opioid receptor (MOR)-Luc and AT1R-eGFP. The BRET signal between AT1R and CB 1 R was decreased upon coexpression of untagged AT1R, but not another membrane protein, endothelin converting enzyme-2, indicating competition between the tagged and untagged AT1R for interaction with CB 1 R and the specificity of AT1R-CB 1 R interaction.
Finally, we detected AT1R-CB 1 R heteromers using heteromer-specific antibodies. For this, we developed monoclonal antibodies specifically directed against the AT1R-CB 1 R heteromer using a strategy employed for the generation of monoclonal antibodies against the MOR-delta opioid receptor (DOR) heteromer (Gupta et al, 2010) ; these antibodies are useful to monitor the changes in heteromer abundance in different pathophysiological paradigms. For the subtractive immunization strategy, mice were first made tolerant to non-preferred epitopes on membrane proteins by the simultaneous administration of Neuro2A cell membranes and cyclophosphamide, which causes the death of antibody-generating activated B cells (Salata et al, 1992; Rao, 2001, 2002) . Once a low titre to Neuro2A cell membrane proteins was achieved, mice were immunized with membranes from Neuro2A cells coexpressing AT1R-CB 1 R (desired epitope). The spleens of mice with high antibody titres were used to generate monoclonal antibodies. The supernatants from the resultant hybridoma clones were screened with Neuro2A cell membranes alone, membranes from HEK293 cells expressing only AT1R, and membranes from Neuro2A cells coexpressing both AT1R and CB 1 R. This led to the identification of a number of antibody-secreting clones that gave a high signal with membranes from cells coexpressing AT1R and CB 1 R, but not with membranes from cells expressing only AT1R or CB 1 R (Supplementary Figure S3A) , nor with cells coexpressing CB 1 R with CB 2 R, DOR, MOR, or KOR, or cells expressing DOR with KOR or MOR (Supplementary Figure S3B) . To further characterize the specificity of the antibody, we used cells expressing different ratios of CB 1 R and AT1R and find that there is maximal recognition by the heteromer antibody only when CB 1 R and AT1R are expressed at similar levels (but not when the relative levels of one or the other receptor was significantly altered) (Supplementary Figure S3C) . Finally, we examined the specificity of these antibodies, by their ability to detect the AT1R-CB 1 R epitope in Neuro2A, Neuro2A-AT1R, and Neuro2A-AT1R in which CB 1 R expression was downregulated by RNAi. We find that the antibodies recognized the specific AT1R-CB 1 R epitope only in Neuro2A-AT1R, but not in cells where one of the receptors is absent or downregulated ( Figure 2D ). Taken together, these results indicate that the antibodies exhibit heteromer specificity and can be used to study AT1R-CB 1 R heteromer properties. We then used the heteromer-specific antibody to block AT1R-CB 1 R heteromer-mediated signalling, and found that the antibody was able to block Ang IImediated ERK phosphorylation in a dose-dependent manner, in cells expressing both receptors, but not in cells where CB 1 R levels were reduced by RNAi-mediated downregulation ( Figure 2E ); this suggests that the response to Ang II is mediated by the AT1R-CB 1 R heteromer.
To further examine if the changes in AT1R signalling in the presence of CB 1 R were due to heteromerization and were not the consequence of a cross-talk between downstream signalling cascades, we examined the impact of blocking CB 1 R on the G protein coupling to AT1R. [
35 S]GTPgS-binding experiments indicate that blocking CB 1 R with a specific antagonist leads to a decrease in the efficacy of Ang II ( Figure 2F ). We tested the specificity of the heteromer-mediated signalling by examining if CB 1 R activity could regulate the signalling of a non-GPCR, such as PDGFR. Treatment with either two different CB 1 R antagonists or with a low concentration of a CB 1 R agonist did not affect PDGFbb-mediated ERK phosphorylation (Supplementary Figure S4A and B) . We also examined if the increase in Ang II-mediated ERK phosphorylation in the presence of CB 1 R could be the result of a non-specific 'presensitization' of the ERK pathway. For this, we stimulated Neuro2A-AT1R cells with a 'subphysiological' dose of PDGFbb and examined the effect on Ang II-mediated ERK phosphorylation. We found that PDGFbb treatment neither altered Ang II-mediated signalling nor rescued this signalling in conditions where CB 1 R was blocked with an antagonist (Supplementary Figure S4C) . These results exclude the contribution of an alternate mechanism for AT1R-CB 1 R crosstalk. Finally, it has been shown for other receptor pairs that, within a heterodimer, the effect of one protomer on the other is bidirectional . We directly examined this by investigating the changes in CB 1 R signalling levels in the presence of an unstimulated AT1R (as we showed that unstimulated CB 1 R inhibited AT1R-mediated ERK phosphorylation; Figure 1C and D). Stimulation of CB 1 R in Neuro2A cells led to a dose-dependent increase in pERK levels ( Figure 2G ). This was abolished in the presence of AT1R (in Neuro2A-AT1R cells), but restored when stimulating AT1R with an agonist dose which does not induce a measurable signal (0.01 nM of Ang II) ( Figure 2G ). This reciprocal regulation of CB 1 R signalling by AT1R further supports a heteromermediated cross-talk.
Altogether, these results support the notion that the functional interaction between AT1R and CB 1 R occurs at the receptor level, through receptor heteromerization.
CB 1 R induces a dissociation of the effectors leading to calcium and ERK signalling
In order to explore the specific signalling of the AT1R-CB 1 R heteromer, we first investigated the nature of the G protein that is coupled to AT1R (which classically couples to Gaq) in Neuro2A-AT1R cells. Expression of a dominant-negative (DN) Gaq did not lead to a decrease (but led to an unexpected increase) in Ang II-mediated pERK ( Figure 3A and C), suggesting that in the context of the AT1R-CB 1 R heteromer, AT1R does not couple to Gaq. This is supported by our results showing that expression of DN Gaq under conditions of CB 1 R downregulation led to a substantial inhibition of AT1R signalling ( Figure 3B and C), indicating that in the absence of CB 1 R, AT1R couples to its classical effector, Gaq. These results suggest that in the presence of CB 1 R, AT1R uses a different G protein for signalling to the ERK pathway. Next, we examined the involvement of Gai using pertussis toxin (PTX; that blocks Gai). This treatment markedly inhibited AT1R signalling (by 480%) only in cells coexpressing CB 1 R and AT1R ( Figure 3D and F), but not in cells expressing AT1R alone, that is, upon downregulation of CB 1 R expression ( Figure 3E and F) . These results are consistent with the notion that in the presence of CB 1 R, AT1R couples to Gai for signalling to the ERK pathway. We assessed the specificity of this switch in coupling of AT1R by examining the sensi-tivity to PTX of Ang II-mediated ERK phosphorylation, when AT1R was coexpressed with other Gai-coupled receptors, namely MOR or DOR. We found that PTX prevents Ang IImediated ERK phosphorylation, only when AT1R is coexpressed with CB 1 R, but not when expressed alone or with the other Gai-coupled receptors (Supplementary Figure S4E) , supporting the specificity of the switch in G protein coupling to the AT1R-CB 1 R heteromer.
We then examined if AT1R coupling to Gai led to inhibition of cAMP production by Ang II treatment. In Neuro2A-AT1R cells, Ang II stimulation led to a dose-dependent inhibition of cAMP production, supporting a coupling to Gai. This effect was blocked by co-treatment with the CB 1 R antagonist PF514273 and was markedly decreased upon RNAi-mediated downregulation of CB 1 R (Figure 4A and C) . This regulation of cAMP production by heteromerization was also reciprocal, F 0 1 e -1 1 1 e -1 0 1 e -9 3 e -9 1 e -8 1 e -8 3 e -9 1 e -9 1 e -1 0 1 e -1 1 0 pERK ERK pERK ERK 0 1 e -1 1 1 e -1 0 1 e -9 3 e -9 1 e -8 0 1 e -1 1 1 e -1 0 1 e -9 3 e -9 1 e -8 since the presence of unstimulated AT1R impaired the inhibition of cAMP production induced by the CB 1 R agonist Hu210 ( Figure 4B and C). These experiments confirm that in the context of the AT1R-CB 1 R heteromer, AT1R couples to Gai, and that the basal activity of CB 1 R is required for this pathway.
We next examined if this change in coupling results in further downstream changes in signalling pathway such as those leading to ERK phosphorylation. While the PKC inhibitor calphostin C attenuated Ang II-mediated ERK phosphorylation in cells where CB 1 R was downregulated, it had no effect on Ang II-mediated ERK phosphorylation in Neuro2A-AT1R cells (Supplementary Figure S5A) . We also found that PLC is involved in Ang II-mediated ERK phosphorylation irrespective of the presence of CB 1 R. These suggest a dissociation between PLC and PKC for Ang II-mediated pERK in CB 1 R-expressing cells, in agreement with previous reports (Ma 'ayan et al, 2009 ). In addition, we found a switch in the role of Arrestin3 in the regulation of ERK signalling upon heteromerization of AT1R with CB 1 R; while, as previously described, Arrestin3 contributes to Ang II-mediated ERK phosphorylation (Ahn et al, 2004; Supplementary Figure S5B) , in the presence of CB 1 R, downregulation of Arrestin3 leads to an increase in pERK, indicating a role for Arrestin3 in the desensitization of AT1R within the heteromer (Supplementary Figure S5B) .
We also examined if signalling events classically mediated by AT1R, namely the mobilization of calcium from intracellular stores via a mechanism mediated by coupling to Gaq, were altered in the context of the AT1R-CB 1 R heteromer. Stimulation of heteromer expressing cells with Ang II led to a marked increase in intracellular calcium levels ( Figure 5A ; Supplementary Figure S6C ). This was largely prevented by expression of DN Gaq (by B60%), but was not affected by treatment with PTX ( Figure 5A and E), indicating that Ang II stimulation leads to a Gaq-mediated increase in intracellular calcium concentration. RNAimediated CB 1 R downregulation led to a decrease (by B50%) of this signalling response ( Figure 5B and E), which was not affected by PTX treatment ( Figure 5C ), suggesting that CB 1 R contributes to Ang II signalling by the Gaq pathway. This is supported by our results showing that treatment with the CB 1 R-specific antagonist SR141716 also led to a decrease (B50%) of Ang II-mediated increase in intracellular calcium concentration ( Figure 5D and E). In contrast, CB 1 R stimulation with Hu210 did not lead to an increase in intracellular calcium levels in either Neuro2A or Neuro2A-AT1R cells in the absence of concomitant stimulation of AT1R ( Figure 5F ; Supplementary Figure S6A and B). However, Hu210 was able to potentiate Ang II-mediated signalling ( Figure 5F ; Supplementary Figure S6D and E), supporting our previous results that CB 1 R activation enhances AT1R activity.
In control experiments, we examined the influence of other Gai-coupled receptors on AT1R-mediated Gaq signalling. We observed that co-stimulation of MOR with its agonist DAMGO, but not co-stimulation of DOR with its agonist deltorphin was potentiating Ang II response (Supplementary Figure S4E) . These results further support the specificity of the functional interaction between CB 1 R and AT1R, affecting both Gai-and Gaq-mediated responses, as opposed to interactions between MOR and AT1R that affect only Gaq-mediated response, and the absence of measurable functional interaction between DOR and AT1R.
Taken together with the finding that Ang II-mediated ERK phosphorylation is via the Gai/o-mediated pathway, these results indicate that AT1R-CB 1 R heteromer recruits both Gaq (to mediate calcium signalling) and Gai (to mediate ERK signalling), and that signalling via both these G proteins is controlled by CB 1 R activity, and enhanced by CB 1 R basal activation. Hence, AT1R-CB 1 R heteromer functions as a signal integrator and enhances the repertoire of AT1R and CB 1 R signalling.
CB 1 R interacts with AT1R in activated HSCs
Activation of HSCs is the dominant event in liver fibrogenesis and proceeds along a continuum that involves progressive changes in cellular function. Activated HSCs produce excess extracellular matrix proteins, including collagens, resulting in fibrosis (Friedman, 2008) . Cannabinoid receptors exhibit marginal expression in the normal liver but an enhanced expression in the fibrotic human liver, predominantly in activated HSCs (Teixeira-Clerc et al, 2006) . CB 1 R contributes to fibrogenesis, since administration of the CB 1 R antagonist rimonabant (SR141716) or genetic ablation of CB 1 R inhibits fibrosis progression in three models of chronic liver injury (namely, CCl4-, thioacetamide-, and bile duct ligation-induced fibrosis) (Teixeira-Clerc et al, 2006) . However, the molecular mechanism by which CB 1 R promotes HSC activation and liver fibrosis are not understood. Given the potentiation of Ang II signalling by heteromerization of AT1R with CB 1 R, and the profibrogenic properties of hyperreactive AT1R (Billet et al, 2008) , we hypothesized that upregulated CB 1 R could interact with AT1R, a resident receptor in HSCs and facilitate AT1R profibrogenic activity.
First, we examined the relative abundance of AT1R and CB 1 R in HSCs from control rats (cHSCs) or rats treated with ethanol for 8 months (eHSCs) (see details in 'Materials and methods'). Activation of the eHSCs was supported by a substantial increase in the levels of a-smooth muscle actin (a-SMA), a marker of HSC activation ( Figure 6A ). We found that CB 1 R was markedly upregulated (B7-fold) and AT1R was modestly upregulated (B1.5-fold) in eHSCs compared with cHSCs ( Figure 6A ). Similar changes in receptor expression were measured by radioligand binding (Table I ). These results indicate that chronic ethanol treatment leads to upregulation of CB 1 R in HSCs, in agreement with the upregulation of CB 1 R observed in other models of liver injury (TeixeiraClerc et al, 2006) .
Next, we examined direct interaction between CB 1 R and AT1R in these cells and found that CB 1 R could be detected in the AT1R immunoprecipitate only from activated but not from control HSCs (Figure 6B ), supporting heteromerization of AT1R-CB 1 R specifically in activated HSCs. Using the AT1R-CB 1 R heteromer-selective antibody, we found substantial AT1R-CB 1 R immunoreactivity in activated HSCs but not Lysates from cHSCs and eHSCs were subjected to immunoprecipitation using an anti-AT1R antibody (1 mg)/protein A/G agarose, and to western blotting analysis with CB 1 R antibody (1:500). CB 1 R is detected in the AT1R immunoprecipitate from eHSCs (and not cHSCs). (C) Detection of AT1R-CB 1 R heteromers with heteromer-selective monoclonal antibodies. Receptor abundance was determined in cHSCs and eHSCs with a monoclonal antibody to AT1R-CB 1 R by ELISA. Results represent the means±s.e.m. obtained with antibodies from seven different hybridoma clones. ***Po0.001. (D) Colocalization of AT1R and CB 1 R in activated HSCs. eHSCs grown on coverslips were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, and stained with primary rabbit polyclonal anti-CB 1 R (1:500) and goat polyclonal anti-AT1R (1:200) antibodies. After fluorescent secondary antibody staining, the coverslips were mounted with mowiol. Slides were examined with a Leica SP5 confocal microscope. (Figure 6C ), supporting higher levels of AT1R-CB 1 R heteromer in activated HSCs. Finally, CB 1 R and AT1R were colocalized at the cell surface of the activated HSCs, in agreement with their presence in heteromeric complexes ( Figure 6D ).
CB 1 R activity governs Ang II-mediated signalling in activated HSCs
Next, we examined if in HSCs, AT1R was hyperreactive and if CB 1 R had a role in this response. Treatment with Ang II led to a marked increase in pERK levels in activated HSCs ( Figure 7A and B) above the level seen in control HSCs (Figure 7C and D) . This increase in signalling was dependent on CB 1 R since treatment with a CB 1 R-specific antagonist as well as blocking the formation of the endocannabinoid 2-AG with THL blocked Ang II response in activated HSCs ( Figure 7 Regulation of AT1R responses by CB 1 R in activated HSCs. (A) eHSCs were stimulated for 10 min with 1 mM Ang II in the absence or presence of SR141716 (SR, 1 mM) and the levels of pERK and ERK examined as described in 'Materials and methods'. Data are expressed as the mean ± s.e.m. (n ¼ 3 independent experiments). **Po0.01. (B) eHSCs were treated with THL (1 mM, for 0, 10, or 30 min) before treatment with Ang II (1 mM). Data are expressed as the mean±s.e.m. (n ¼ 3 independent experiments). *Po0.05; **Po0.01. (C) cHSCs were stimulated for 10 min with 1 mM Ang II in the absence or presence of SR141716 (SR) and the levels of pERK and ERK examined as described in 'Materials and methods'. (D) cHSCs pretreated with THL for 10 or 30 min were stimulated with 1 mM Ang II. Lysates were subjected to SDS-PAGE and immunoblotting. The levels of Ang II-mediated pERK normalized to total ERK are indicated. Data are expressed as the mean ± s.e.m. (n ¼ 3-4 independent experiments). (E) eHSCs and cHSCs in 24-well plates were incubated with increasing concentrations of Ang II in the absence or presence of the CB 1 R antagonist PF514273 (1 mM) at 371C for 15 min in the cAMP treatment buffer (0.5 mM isobutylmethylxanthine and 10 mM forskolin in Krebs-Ringer-HEPES buffer). After terminating the reaction by heating at 951C, cAMP concentrations were determined as described in 'Materials and methods'. Data are expressed as the mean±s.e.m. (n ¼ 3 independent experiments). ***Po0.001. (F) eHSCs were stimulated with Ang II (1 mM) in the absence or presence of SR141716 (SR, 1 mM) or of PD98059 (MEK inhibitor, 10 mM) for 4 h before the RNA was harvested. After reverse transcription, the number of copies of mRNA for the indicated transcripts were determined by real-time PCR. Data were normalized to GAPDH mRNA and are expressed as the mean ± s.e.m. (n ¼ 3 in quadruplicate). *Po0.05; **Po0.01 (versus Ang II treatment); NS, non-significant (Ang II þ PD98059 versus Ang II þ SR). 7A and B) but not in control HSCs (Figure 7C and D) . These results are consistent with the idea that CB 1 R and the endocannabinoid tone control the signalling of AT1R in the context of AT1R-CB 1 R heteromers present in activated HSCs. We also examined if AT1R couples to Gai in the presence of CB 1 R in HSCs. In activated HSCs, Ang II treatment led to a dose-dependent inhibition of cAMP production ( Figure 7E) . Blockade of this effect by the CB 1 R antagonist PF514273 as well as absence of inhibition of cAMP levels in control HSCs (that do not express CB 1 R), support a role for heteromerization with CB 1 R in facilitating the coupling of AT1R to Gai in activated HSCs.
Modulation of AT1R profibrogenic activity by CB 1 R Next, we examined if we could target the AT1R-CB 1 R heteromer to block Ang II-mediated HSC activation. In activated HSCs, we found that stimulation of AT1R led to an increase in expression of the profibrogenic markers a-SMA, TGF-b, procollagen aIII, and pro-collagen aI by as much as 120-160% over baseline; this increase could be completely blocked by treatment with the CB 1 R antagonist SR141716, or with the MEK inhibitor PD98059 ( Figure 7F ), indicating that the profibrogenic potential of AT1R requires CB 1 R activity and that CB 1 R-AT1R heteromer could represent a novel diseasespecific therapeutic target.
Discussion
In this study, we show that when coexpressed, CB 1 R and AT1R physically and functionally interact in recombinant as well as in endogenous systems. Interaction with CB 1 R confers new signalling properties to AT1R including a change in G protein coupling, and enhanced responsiveness to Ang II. This mechanism allows for a regulation of AT1R responses by CB 1 R expression levels, underscoring the relevance of CB 1 R upregulation during chronic diseases on the function and properties of other coexpressed receptors.
Cross-talk between Gai-and Gaq-coupled receptors has been described for several receptor pairs, and typically leads to a potentiation of Gaq signalling (Carroll et al, 1995; Hilairet et al, 2003; Rives et al, 2009) , found often to be heteromerization independent (Rives et al, 2009) . However, other studies have convincingly reported heteromerizationdependent cross-talk between Gai-and Gaq-coupled receptors, either involving a class A and a class C receptors (Gonzalez-Maeso et al, 2008) or two class A receptors (Breit et al, 2006) . In the present study, using a variety of methods such as co-immunoprecipitation, BRET assays, heteromer-selective antibody detection, and changes in receptor subcellular localization, we demonstrate physical interactions between two class A GPCRs, AT1R, and CB 1 R.
While the cross-talk between Gai-and Gaq-coupled receptors involving class C GPCRs has been shown to lead to a potentiation of the Gaq-mediated pathway, AT1R-CB 1 R heteromerization appears to lead to a more complex scenario. In addition to a potentiation of the Gaq-mediated signalling, as measured by an increase in Ang II-mediated calcium response by CB 1 R basal activity (and by CB 1 R agonist stimulation), heteromerization with CB 1 R also potentiates a Gai-mediated mitogenic signalling in response to Ang II. This coupling to Gai, confirmed by sensitivity to PTX and by the inhibition of cAMP production, suggests a unique signalling property of the receptor complex that differs from the cross-talk between Gai-and Gaq-coupled receptors involving class C GPCRs (Rives et al, 2009 ). This mechanism is also different from that of the sensory neuron-specific receptor-4 (SNSR-4)-DOR heteromer for which concomitant activation of the Gaicoupled DOR and Gaq-coupled SNSR-4 led to the inhibition of the Gai signalling and full activation of the Gaq-mediated phospholipase C pathway (Breit et al, 2006) .
The potentiation of AT1R signalling by heteromerization with CB 1 R results in the enhancement of the mitogenic signalling and profibrogenic activity of AT1R. Using a transgenic mouse harbouring a hyperreactive mutant of AT1R, that exhibits enhanced signalling in response to Ang II, it was demonstrated that hyperreactivity of AT1R can be responsible for deleterious, in particular profibrogenic, effects of Ang II (Billet et al, 2007) . However, no such 'gain of function' mutations of AT1R within its coding region have been identified (Davies et al, 1997; Sachse et al, 1997) , suggesting that alternative molecular mechanisms could be responsible for the 'gain of function'-like phenotype of AT1R in diseases. We propose that association with CB 1 R is sufficient to confer hyperreactivity to AT1R. We find that basal activity of CB 1 R enhances Ang II-mediated signalling, and that blocking CB 1 R leads to a decrease in AT1R responsiveness to Ang II, suggesting that CB 1 R within the AT1R-CB 1 R heteromer, confers a 'gain of function'-like hyperreactive property to AT1R, underscoring the relevance of AT1R-CB 1 R heteromerization in pathology.
Mechanisms of cross-talk between AT1R and CB 1 R, at both the transcriptional and signalling levels, have been reported. CB 1 R activity has been involved in regulating AT1R expression in endothelial cells (Tiyerili et al, 2010) and AT1R has been involved in regulating the activity of the endocannabinoid biosynthetic enzyme DAGL (Turu et al, 2007) . This latter study elegantly demonstrated that activation of AT1R leads to a Gaq-mediated increase in intracellular calcium, which in turn activates the calcium-dependent DAGL, leading to increased production of 2-AG, resulting in enhanced basal activity of CB 1 R (Turu et al, 2007) . While these studies demonstrate indirect cross-regulation between CB 1 R and AT1R, to date, mechanisms involving direct protein-protein interaction between these two receptors affecting their function had not been explored. In the present study, we demonstrate the regulation of AT1R by CB 1 R through receptor heteromerization. The hyperreactivity of AT1R described herein cannot be the consequence of transcriptional regulation of its expression, since expression or abundance of AT1R are not significantly changed in the presence of CB 1 R, in any of the models used. Furthermore, the alteration of AT1R properties by CB 1 R occurs in endogenous systems as well as in heterologous cells (where transfected AT1R is not subject to transcriptional regulation). In addition, the hyperreactivity of AT1R described herein does not involve the regulation of DAGL activity by AT1R, since directly blocking CB 1 R with a specific antagonist prevents Ang II-mediated signalling. In addition, the reciprocity of the regulation of receptor activity by heteromerization (i.e., the functional inhibition of CB 1 R activity by AT1R) further confirms the absence of effect of DAGL activity on our observations. Taken together, our studies strongly support AT1R-CB 1 R heteromerization as a mechanism for the altered properties of AT1R. Our finding that AT1R-CB 1 R heteromerization facilitates profibrogenic signalling, together with the possibility of auto and paracrine transactivation of CB 1 R by AT1R (described above), suggest complementary mechanisms that converge towards upregulation of profibrogenic stimulation.
Another important finding in this study is that the basal activity of CB 1 R is sufficient to enhance the activity of associated AT1Rs underscoring a particularly important role for the endocannabinoid tone in the maintenance of fibrosis. It is likely that this mechanism of 'hijacking' of receptor activity by the upregulated CB 1 Rs has a role in additional pathologies, particularly in the case of metabolic syndrome where CB 1 R expression is increased in select tissues . One could propose that, as seen in activated HSCs, CB 1 R could interact with AT1R in hepatocytes and adipocytes where CB 1 R expression is increased during disease (Bensaid et al, 2003; Jeong et al, 2008) . The generalization of this mechanism is further supported by the observation that in the presence of CB 1 R, orexin receptormediated signalling was enhanced and found to be PTX sensitive and could be blocked by a CB 1 R antagonist (Hilairet et al, 2003) .
Previous studies exploring the role of GPCR heteromers in disease (AbdAlla et al, 2001 (AbdAlla et al, , 2005 have led to the proposal that upregulated heteromers during pathologies represent potential drug targets . The evidence for disease-specific AT1R-CB 1 R receptor interaction further suggests that this complex could represent a novel drug target for anti-fibrotic compounds, allowing selective peripheral targeting of CB 1 R, and thereby preventing the psychoactive effects of CB 1 R antagonists (Kunos et al, 2009 ).
Materials and methods

Cell lines, reagents, and plasmids
Human embryonic kidney (HEK)-293 and Neuro2A cells from ATCC were maintained in DMEM þ 10% FBS at 371C in a humidified 5% CO 2 incubator. HSCs were maintained in DMEM/F12 50% (v/ v) þ 10% FBS. Rabbit monoclonal anti-phospho-ERK and mouse monoclonal anti-ERK antibodies were from Cell Signaling Technology Inc. Polyclonal anti-Calnexin, monoclonal anti-Flag antibodies, PTX, and THL were from Sigma. Rabbit and goat polyclonal anti-AT1R, polyclonal anti-Gaq, polyclonal anti-HA antibodies, protein A agarose-coupled anti-CB 1 R antibody, CB 1 R and control siRNAs, and coelenterazine A were from Santa Cruz Biotechnology. Rabbit polyclonal anti-CB 1 R antibody used for western blotting was from Cayman Chemicals, and rabbit polyclonal anti-CB 1 R antibody used for immunostaining was a gift from Dr Ken Mackie (University of Indiana). Monoclonal anti-a-SMA antibody was from Abcam. The secondary antibodies IRDye 680-labelled anti-rabbit antibody, IRDye 800-labelled anti-mouse, and anti-goat antibodies were from Rockland Immunochemicals (Gilbertsville, PA). Hu210, Ang II, and PF514273 were from Tocris Bioscience. SR141716 was from NIDA drug support program. DN Gaq (Q209L/D277N) plasmid was a gift from Dr Ken Mackie (University of Indiana).
HSC isolation
HSCs from ethanol-treated rats were generated as described (Cubero and Nieto, 2008) . Rats (300 g female Sprague-Dawley, N ¼ 10/group) were fed the control or ethanol Lieber-DeCarli diets for 8 months (Lieber and DeCarli, 1989) . Animals received humane care according to the criteria outlined in the Guide for Care and Use of Laboratory Animals. Details regarding pathology of the liver of the control and alcohol-fed rats are described in Cubero and Nieto (2008) and Urtasun et al (2009) . Briefly, haematoxylin and eosin staining showed microvesicular and macrovesicular steatosis in livers from ethanol-fed rats; transaminases and non-esterified fatty acids were elevated two-fold and six-fold, respectively, in the ethanol-fed rats.
Plasmid and siRNA transfections were carried out as described (Rozenfeld and Devi, 2007) .
Co-immunoprecipitation and western blotting
Cells were lysed for 1 h in lysis buffer (1% Triton, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 50 mM Tris-Cl, pH 7.4) containing protease inhibitor cocktail (Sigma). For immunoprecipitation, cell lysates containing 400-600 mg of protein were incubated with the anti-AT1R antibody (1 mg)/protein A/G agarose complex or with a protein A agarose-coupled anti-CB 1 R antibody (1 mg) overnight at 41C. The beads were washed three times with lysis buffer and once with the same buffer without detergent. Proteins were eluted in 60 ml of 2Â Laemmli buffer containing 1% 2-mercaptoethanol. Proteins were resolved by 10% SDS-PAGE, and subjected to western blotting as described (Rozenfeld and Devi, 2008) .
Immunofluorescence and confocal microscopy was carried out as described (Rozenfeld and Devi, 2008) . Slides were visualized with a Leica TCS SP5 confocal microscope. Images were acquired with Â 63/1.32 PL APO objective lens, and analysed in sequential scanning mode.
Western blot and phospho-ERK assays were carried out as described in the case of experiments with Neuro2A cells (Rozenfeld and Devi, 2008) . In all cases, the cells were starved at least 4 h before the treatments. For experiments with HSCs, freshly plated cells were stimulated for 10 min with 1 mM Ang II in the presence or absence of SR141716 or THL (as indicated). Phospho-ERK and ERK were detected with rabbit monoclonal anti-phospho-p44/42 MAPK (anti-pERK, 1:1000) and mouse monoclonal anti-p44/42 MAPK (anti-ERK, 1:1000) antibodies. Both blotting and imaging with the Odyssey imaging system (LI-COR, Lincoln, NE) were performed following the manufacturer's protocols. The secondary antibodies that were used included: IRDye 680-labelled anti-rabbit antibody, IRDye 800-labelled anti-mouse, and anti-goat antibodies (1: 10 000).
Subtractive immunization
For induction of tolerance to immunogenic epitopes in Neuro2A cell membranes, female balb/c mice (6-8 weeks old, 25-35 g body weight) were injected intraperitoneally (i.p.) with 5 mg/kg Neuro2A cell membranes and 15 min later with cyclophosphamide (100 mg/ kg body weight, i.p.). The cyclophosphamide injection was repeated after 24 and 48 h, respectively. Mice were bleed every 15 days and antibody titres checked by ELISA against Neuro2A cell membranes. This protocol was repeated at 2-week intervals until stable background titres were obtained with Neuro2A cell membranes. Mice were then given an i.p. injection of membranes from Neuro2A cell expressing AT1R (in addition to CB 1 R endogenously expressed) (5 mg/kg) in complete Freund's adjuvant. Booster i.p. injections of Neuro2A cell membranes expressing AT1R were administered every 15 days. Antibody titres were checked by ELISA against Neuro2A cell membranes from untransfected cells and from cells expressing AT1R, as described for MOR-DOR (Gupta et al, 2010) . Spleens from animals giving a high titre with Neuro2A cell membranes expressing AT1R receptors were fused with SP-20 myeloma cells to generate monoclonal antibodies as described. Clones secreting monoclonal antibodies were screened by ELISA against untransfected Neuro2A cell membranes, and HEK293 membranes expressing AT1R or Neuro2A cell membranes expressing AT1R using 1:10 hybridoma supernatant and 1:500 horseradish peroxidase labelled anti-mouse IgG.
ELISAs were carried out as previously described (Gupta et al, 2007) with cells (2 Â10 5 /well) expressing individual receptors or with cells coexpressing AT1R and CB 1 R, or the indicated GPCRs.
[
S]GTPcS binding
Membranes from Neuro2A-AT1R cells were prepared by homogenization in ice-cold 50 mM Tris-Cl buffer pH 7.4 containing 1 mM EDTA and 10% sucrose. The membranes were incubated with increasing concentrations of Ang II ± PF514273 (1 mM) in the presence of 100 mM GDP and 0.1 nM [
35 S]GTPgS. Basal binding was determined in the presence of GDP and absence of agonist and cold GTPgS. Non-specific binding was determined by adding 10 mM GTPgS to a parallel set of tubes.
